PROCEPT BioRobotics Co. (NASDAQ:PRCT) Shares Sold by Legato Capital Management LLC

Legato Capital Management LLC lessened its stake in PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 32.0% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 31,167 shares of the company's stock after selling 14,663 shares during the period. Legato Capital Management LLC owned 0.06% of PROCEPT BioRobotics worth $2,510,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the stock. State Street Corp increased its position in PROCEPT BioRobotics by 5.9% during the 3rd quarter. State Street Corp now owns 1,179,514 shares of the company's stock worth $94,503,000 after purchasing an additional 66,175 shares during the period. Geode Capital Management LLC increased its position in PROCEPT BioRobotics by 8.2% during the 3rd quarter. Geode Capital Management LLC now owns 1,106,588 shares of the company's stock worth $88,678,000 after purchasing an additional 84,244 shares during the period. Westfield Capital Management Co. LP acquired a new position in PROCEPT BioRobotics during the 3rd quarter worth approximately $72,563,000. Franklin Resources Inc. increased its position in PROCEPT BioRobotics by 64.5% during the 3rd quarter. Franklin Resources Inc. now owns 885,992 shares of the company's stock worth $64,669,000 after purchasing an additional 347,330 shares during the period. Finally, Perpetual Ltd acquired a new position in PROCEPT BioRobotics during the 4th quarter worth approximately $66,972,000. Institutional investors and hedge funds own 89.46% of the company's stock.

Insider Activity at PROCEPT BioRobotics

In other PROCEPT BioRobotics news, CEO Reza Zadno sold 26,423 shares of the stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $97.22, for a total transaction of $2,568,844.06. Following the transaction, the chief executive officer now owns 152,762 shares of the company's stock, valued at $14,851,521.64. This represents a 14.75 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Alaleh Nouri sold 28,092 shares of the stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $97.13, for a total value of $2,728,575.96. Following the transaction, the executive vice president now directly owns 52,472 shares in the company, valued at approximately $5,096,605.36. This represents a 34.87 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 107,355 shares of company stock valued at $10,327,788. 17.40% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. Wells Fargo & Company reiterated an "overweight" rating and set a $112.00 target price on shares of PROCEPT BioRobotics in a research report on Tuesday, December 3rd. Jefferies Financial Group began coverage on PROCEPT BioRobotics in a research report on Thursday, November 14th. They set a "hold" rating and a $95.00 target price on the stock. Morgan Stanley began coverage on PROCEPT BioRobotics in a report on Monday, December 2nd. They issued an "overweight" rating and a $105.00 price target on the stock. Finally, Truist Financial restated a "buy" rating and issued a $105.00 price target (up previously from $95.00) on shares of PROCEPT BioRobotics in a report on Wednesday, October 30th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $97.86.

PROCEPT BioRobotics Price Performance

PRCT stock traded down $1.66 on Friday, reaching $67.61. The company had a trading volume of 842,466 shares, compared to its average volume of 927,178. PROCEPT BioRobotics Co. has a 1 year low of $45.20 and a 1 year high of $103.81. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.07 and a current ratio of 6.02. The company's fifty day moving average is $79.01 and its 200 day moving average is $79.52. The company has a market cap of $3.53 billion, a P/E ratio of -34.67 and a beta of 1.03.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).